BioMarin Pharmaceutical Inc (BMRN) stock
BMRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 3, 2026Score 8/3091% above fair value
$57.23+0.53 (+0.93%)
Close on Nov 13, 2026Market cap $11.08BP/E 150.6Yield –
BioMarin Pharmaceutical enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
BioMarin Pharmaceutical's enterprise value was $14.60B on Nov 11, 2026, against $9.27B a year earlier. Over the last 5 years it ranged from $8.84B to $20.16B, with a median of $14.27B.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $14.60B | +46.9% |
| 2025 | Dec 31, 2025 | $9.94B | -14.3% |
| 2024 | Dec 31, 2024 | $11.59B | -31.9% |
| 2023 | Dec 29, 2023 | $17.03B | -5.1% |
| 2022 | Dec 30, 2022 | $17.96B | +18.6% |
| 2021 | Dec 31, 2021 | $15.14B | +5.1% |
| 2020 | Dec 31, 2020 | $14.41B | -0.4% |
| 2019 | Dec 31, 2019 | $14.46B | +5.5% |
| 2018 | Dec 31, 2018 | $13.71B | -4.8% |
| 2017 | Dec 29, 2017 | $14.39B | +9.1% |
| 2016 | Dec 30, 2016 | $13.19B | -18.9% |
| 2015 | Dec 31, 2015 | $16.27B | +28.5% |
| 2014 | Dec 31, 2014 | $12.66B | +31.6% |
| 2013 | Dec 31, 2013 | $9.62B | +69.9% |
| 2012 | Dec 31, 2012 | $5.66B | +53.1% |
| 2011 | Dec 30, 2011 | $3.70B | +53.7% |
| 2010 | Dec 31, 2010 | $2.41B | +39.5% |
| 2009 | Dec 31, 2009 | $1.73B | – |
See a number that looks wrong?